EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 2025 financial results and significant progress in its DURAVYU鈩� development program for wet AMD. The company successfully completed enrollment for two Phase 3 trials: LUGANO (432 U.S. patients) and LUCIA (over 400 global patients), both achieving unprecedented seven-month enrollment periods.
Q2 2025 financial results showed revenue of $5.3 million, down from $9.5 million in Q2 2024. The company reported a net loss of $59.4 million ($0.85 per share). EyePoint maintains a strong financial position with $256 million in cash, providing runway into 2027, beyond the expected Phase 3 topline data readouts in mid-2026.
The company's Northbridge, MA manufacturing facility is now operational and producing DURAVYU registration batches in preparation for potential FDA approval.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha comunicato i risultati finanziari del secondo trimestre 2025 e i progressi significativi nel programma di sviluppo di DURAVYU鈩� per la degenerazione maculare umida (wet AMD). L'azienda ha completato con successo l'arruolamento per due studi di Fase 3: LUGANO (432 pazienti negli Stati Uniti) e LUCIA (oltre 400 pazienti a livello globale), entrambi con un periodo di arruolamento senza precedenti di sette mesi.
I risultati finanziari del secondo trimestre 2025 mostrano un fatturato di 5,3 milioni di dollari, in calo rispetto ai 9,5 milioni di dollari del secondo trimestre 2024. L'azienda ha registrato una perdita netta di 59,4 milioni di dollari (0,85 dollari per azione). EyePoint mantiene una solida posizione finanziaria con 256 milioni di dollari in liquidit脿, garantendo una copertura finanziaria fino al 2027, oltre le attese per i dati principali di Fase 3 previsti a met脿 2026.
Lo stabilimento produttivo di Northbridge, MA, 猫 ora operativo e sta producendo i lotti di registrazione di DURAVYU in preparazione a una possibile approvazione da parte della FDA.
EyePoint Pharmaceuticals (NASDAQ: EYPT) inform贸 los resultados financieros del segundo trimestre de 2025 y avances significativos en su programa de desarrollo de DURAVYU鈩� para la DMAE h煤meda. La compa帽铆a complet贸 con 茅xito la inscripci贸n para dos ensayos de Fase 3: LUGANO (432 pacientes en EE.UU.) y LUCIA (m谩s de 400 pacientes a nivel mundial), ambos con un per铆odo de inscripci贸n sin precedentes de siete meses.
Los resultados financieros del segundo trimestre de 2025 mostraron ingresos de 5.3 millones de d贸lares, una disminuci贸n respecto a los 9.5 millones del segundo trimestre de 2024. La compa帽铆a report贸 una p茅rdida neta de 59.4 millones de d贸lares (0.85 d贸lares por acci贸n). EyePoint mantiene una posici贸n financiera s贸lida con 256 millones de d贸lares en efectivo, proporcionando recursos hasta 2027, m谩s all谩 de los datos principales esperados de la Fase 3 a mediados de 2026.
La planta de fabricaci贸n en Northbridge, MA, ya est谩 operativa y produce lotes de registro de DURAVYU en preparaci贸n para una posible aprobaci贸n de la FDA.
EyePoint Pharmaceuticals (NASDAQ: EYPT)電� 2025雲� 2攵勱赴 鞛 瓴瓣臣鞕� 鞀奠劚 頇╇皹氤�靹�(wet AMD) 旃橂鞝� DURAVYU鈩� 臧滊皽 頂勲攴鸽灗鞐愳劀鞚� 欷戩殧頃� 歆勳爠鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 霊� 臧滌潣 3靸� 鞛勳儊鞁滍棙鞚� LUGANO (氙戈淡 頇橃瀽 432氇�)鞕� LUCIA (鞝� 靹戈硠 400氇� 鞚挫儊 頇橃瀽)鞚� 霌彪鞚� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, 霊� 鞁滍棙 氇憪 鞝勲 鞐嗠姅 7臧滌洈 霌彪 旮瓣皠鞚� 雼劚頄堨姷雼堧嫟.
2025雲� 2攵勱赴 鞛 瓴瓣臣電� 毵れ稖 530毵� 雼煬搿� 2024雲� 2攵勱赴鞚� 950毵� 雼煬鞐愳劀 臧愳唽頄堨姷雼堧嫟. 須岇偓電� 靾滌啇鞁� 5940毵� 雼煬(欤茧嫻 0.85雼煬)毳� 氤搓碃頄堨姷雼堧嫟. EyePoint電� 2鞏� 5600毵� 雼煬鞚� 順勱笀鞚� 氤挫湢頃橃棳 2026雲� 欷戨皹 鞓堨儊霅橂姅 3靸� 欤检殧 雿办澊韯� 氚滍憸 鞚错泟鞐愲弰 2027雲勱箤歆� 鞛愱笀 鞖挫毄鞚� 臧�電ロ暊 瓴冹溂搿� 氤挫瀰雼堧嫟.
毵れ偓於旍劯旄犾＜ 雲胳姢敫岆Μ歆�鞐� 鞙勳箻頃� 須岇偓鞚� 鞝滌“ 鞁滌劋鞚� 順勳灛 臧�霃� 欷戩澊氅�, FDA 鞀轨澑 臧�電レ劚鞐� 雽�牍勴暣 DURAVYU 霌彪 氚办箻毳� 靸濎偘頃橁碃 鞛堨姷雼堧嫟.
EyePoint Pharmaceuticals (NASDAQ : EYPT) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 ainsi que des progr猫s significatifs dans son programme de d茅veloppement de DURAVYU鈩� pour la DMLA humide. La soci茅t茅 a achev茅 avec succ猫s le recrutement de deux essais de phase 3 : LUGANO (432 patients aux 脡tats-Unis) et LUCIA (plus de 400 patients dans le monde), les deux ayant atteint une p茅riode de recrutement sans pr茅c茅dent de sept mois.
Les r茅sultats financiers du deuxi猫me trimestre 2025 ont montr茅 un chiffre d'affaires de 5,3 millions de dollars, en baisse par rapport 脿 9,5 millions de dollars au deuxi猫me trimestre 2024. La soci茅t茅 a enregistr茅 une perte nette de 59,4 millions de dollars (0,85 dollar par action). EyePoint conserve une position financi猫re solide avec 256 millions de dollars en liquidit茅s, assurant une tr茅sorerie jusqu'en 2027, au-del脿 des r茅sultats principaux attendus de la phase 3 脿 la mi-2026.
L'usine de fabrication de la soci茅t茅 脿 Northbridge, MA, est d茅sormais op茅rationnelle et produit des lots d'enregistrement de DURAVYU en pr茅paration d'une 茅ventuelle approbation par la FDA.
EyePoint Pharmaceuticals (NASDAQ: EYPT) berichtete 眉ber die Finanzergebnisse des zweiten Quartals 2025 und bedeutende Fortschritte im Entwicklungsprogramm von DURAVYU鈩� f眉r die feuchte AMD. Das Unternehmen hat die Rekrutierung f眉r zwei Phase-3-Studien erfolgreich abgeschlossen: LUGANO (432 US-Patienten) und LUCIA (眉ber 400 Patienten weltweit), beide mit einer beispiellosen Einschreibungsdauer von sieben Monaten.
Die Finanzergebnisse f眉r das zweite Quartal 2025 zeigten einen Umsatz von 5,3 Millionen US-Dollar, gegen眉ber 9,5 Millionen US-Dollar im zweiten Quartal 2024. Das Unternehmen meldete einen Nettoverlust von 59,4 Millionen US-Dollar (0,85 US-Dollar pro Aktie). EyePoint verf眉gt 眉ber eine starke finanzielle Position mit 256 Millionen US-Dollar in bar, was eine Finanzierung bis ins Jahr 2027 erm枚glicht, 眉ber die erwarteten Topline-Daten der Phase-3-Studien Mitte 2026 hinaus.
Die Produktionsst盲tte des Unternehmens in Northbridge, MA, ist nun in Betrieb und stellt DURAVYU-Registrierungschargen zur Vorbereitung auf eine m枚gliche FDA-Zulassung her.
- Rapid enrollment completion for both Phase 3 trials (LUGANO and LUCIA) in just seven months
- Strong cash position of $256 million providing runway into 2027
- Commercial manufacturing facility operational and producing registration batches
- Safety profile in Phase 3 trials consistent with previous clinical trials
- EMA approval received for Phase 3 protocols
- Revenue decreased to $5.3 million from $9.5 million year-over-year
- Net loss increased to $59.4 million from $30.8 million year-over-year
- Operating expenses increased significantly to $67.6 million from $44.0 million
- Cash position decreased from $371 million to $256 million since December 2024
Insights
EyePoint shows exceptional clinical execution with completed Phase 3 enrollment for DURAVYU in wet AMD, positioning for potential first-to-market advantage.
EyePoint Pharmaceuticals has demonstrated remarkable operational execution with the rapid completion of enrollment in both pivotal Phase 3 trials (LUGANO and LUCIA) for DURAVYU in wet AMD. The unprecedented seven-month enrollment period for both trials significantly outpaces historical recruitment rates for comparable wet AMD studies, signaling strong physician and patient interest. This accelerated timeline potentially gives EyePoint a critical first-mover advantage in the sustained-release treatment space for wet AMD.
The company's
DURAVYU's development represents a potential paradigm shift in wet AMD treatment. The sustained-release tyrosine kinase inhibitor (TKI) formulation addresses the significant treatment burden of current therapies that require frequent injections. Supporting data presented at ASRS highlights reduced treatment burden versus aflibercept, while maintaining comparable vision outcomes.
Beyond wet AMD, EyePoint is advancing DURAVYU for diabetic macular edema (DME), with a pivotal Phase 3 plan to be announced in H2 2025 following positive FDA End-of-Phase 2 discussions. The 24-week Phase 2 VERONA study results in DME will be presented at the Retina Society Annual Meeting, potentially expanding DURAVYU's addressable market to the second-largest retinal disease indication.
The operational readiness for commercialization is also progressing with registration batches underway at their Northbridge manufacturing facility, designed to meet both FDA and EMA standards. This strategic investment demonstrates management's confidence in eventual approval and anticipated significant market demand.
Strong trial execution and $256M cash runway into 2027 position EyePoint favorably for potential DURAVYU commercialization in the lucrative retinal market.
EyePoint's financial position remains robust with
The
Operating expenses increased
Management's assertion that current cash reserves extend into 2027 is particularly significant as it covers the critical readout period for both Phase 3 wet AMD trials in 2026, eliminating near-term financing pressure during this pivotal value-creation phase. The cash runway beyond data readouts provides negotiating leverage for potential partnerships or strategic alternatives once efficacy is established.
The commercial manufacturing facility in Northbridge represents another strategic investment that reduces future commercialization risk. Having registration batches already underway positions EyePoint to rapidly transition to commercial supply following potential approval, eliminating manufacturing delays that often plague biotech companies post-approval.
With over 800 patients enrolled across two pivotal trials and manufacturing capabilities established, EyePoint has significantly de-risked the development pathway for DURAVYU in the multi-billion dollar wet AMD market, while maintaining financial flexibility through their anticipated approval timeline.
鈥� Completed Phase 3 enrollment for DURAVYU鈩� in wet AMD with over 800 patients enrolled and randomized 鈥�
鈥� LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest 鈥�
鈥� Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow 鈥�
鈥� Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway 鈥�
鈥�
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter ended听June 30, 2025,听and highlighted recent corporate developments.
鈥淚n recent months, we continued our track record of exceptional execution across all aspects of the business, most notably completing enrollment in both pivotal Phase 3 trials, LUGANO and LUCIA, in wet AMD in record time for this indication,鈥� said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. 鈥淭he noteworthy physician and patient enthusiasm we have seen for our Phase 3 program across U.S. and international sites鈥攕upported by DURAVYU鈥檚 robust Phase 2 efficacy and safety data package and our patient-centric, well-understood trial design鈥攈as reinforced the clear need and global demand for more durable wet AMD therapies and the role that DURAVYU can play in meaningfully extending the wet AMD treatment paradigm.鈥�
Dr. Duker continued, 鈥淲ith topline LUGANO data anticipated in mid-2026, LUCIA data to closely follow, and registration batches underway at our state-of-the-art, commercial manufacturing facility in Northbridge, Massachusetts, we believe we are well-positioned for DURAVYU to be first-to-market among investigational sustained release treatments for wet AMD. We look forward to providing an update on our DURAVYU pivotal plan in DME in the coming months as we work to deliver innovative therapeutics for multiple serious retinal diseases.鈥�
R&D Highlights and Updates
- Completed enrollment of Phase 3 wet AMD pivotal program ahead of plan.
- LUGANO and LUCIA are double-masked non-inferiority trials designed to support a clear approval pathway and potential commercial success.
- Both Phase 3 trials experienced unprecedented enrollment exceeding observed recruitment rates of comparable historical and ongoing wet AMD clinical trials
- The oversubscribed LUGANO trial randomized 432 patients in the U.S. in seven months with topline data anticipated in mid-2026.
- LUCIA randomized over 400 patients in the U.S. and in ex-U.S. sites over a seven-month period, with topline data anticipated in the second half of 2026.
- Enrolled the first ex-U.S. patient in the LUCIA trial in Israel with patient participation in sites throughout the Czech Republic, South America, Europe, Australia and India.
- Investigator and patient enthusiasm for the trials underscores the retinal community鈥檚 support and recognition of the clinical rigor underpinning the Phase 3 pivotal program.
- Announced that based on interim masked safety data, the safety profile observed in LUGANO and LUCIA is consistent with previous DURAVYU听clinical trials. In parallel, an independent Data Safety Monitoring Committee (鈥淒SMC鈥�) convened and recommended continuation of the program as planned.
- Received approval of the Phase 3 protocols for the LUGANO and LUCIA trials by the European Medicines Agency (EMA).
- Delivered multiple oral presentations at the American Society of Retina Specialists (ASRS) annual meeting supporting DURAVYU鈥檚 potentially best-in-class therapeutic profile as a sustained release tyrosine kinase inhibitor (TKI) being developed for multiple indications:
- An assessment of the treatment burden in wet AMD treated with DURAVYU versus aflibercept from the Phase 2 DAVIO 2 clinical trial
- Vision outcomes from the DAVIO 2 trial for the treatment of neovascular age-related macular degeneration
- 24-week results from the Phase 2 VERONA clinical trial of DURAVYU versus aflibercept for the treatment of diabetic macular edema (DME)
- Completed a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss pivotal Phase 3 clinical trial plans for DURAVYU in DME. The Company will share details on its DME pivotal plan in the second half of 2025.
- Presented 24-week topline results from the Phase 2 VERONA study in DME at the Retina World Congress in May 2025, highlighting DURAVYU鈥檚 potential to transform the treatment landscape in DME, the second largest retinal disease market, with its best-in-class safety and efficacy profile.
- Accepted to present the Phase 2 VERONA 24-week end-of-study results in DME at the Retina Society Annual Meeting in September, underscoring the broad treatment potential of DURAVYU and enthusiasm from the retinal community for new treatment options in multiple serious retinal diseases.
Recent Corporate Highlights
- Initiated DURAVYU registration batches in support of a potential NDA filing at EyePoint鈥檚 commercial manufacturing facility in Northbridge, Massachusetts. The 41,000-square-foot facility was built to meet both FDA and EMA standards and will have capacity to support the anticipated significant demand for DURAVYU, if approved.
Review of Results for the Second Quarter Ended June 30, 2025
For the second quarter ended June 30, 2025, total net revenue was
Net revenue from license and royalties for the second quarter ended June 30, 2025, totaled
Operating expenses for the second quarter ended June 30, 2025, totaled
Cash, cash equivalents, and marketable securities as of听June 30, 2025 totaled听
Financial Outlook
EyePoint expects its cash, cash equivalents, and marketable securities as of June 30, 2025 will enable the Company to fund operations into 2027 beyond topline Phase 3 data for DURAVYU in wet AMD expected in 2026.
Conference Call Information
EyePoint management will host a conference call today at听8:30 a.m. ET听to discuss the results for the second quarter ended听June 30, 2025,听and recent corporate developments. To access the live conference call, please register using the audio conference link: . A live audio webcast of the event can be accessed via the Investors section of the Company website at听. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company鈥檚 lead product candidate, DURAVYU鈩�, is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E鈩� technology. Supported by robust safety and efficacy data to date, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU鈩� has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Forward Looking Statements
EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans of DURAVYU; our belief that DURAVYU is on track to be the听first-to-market of the current investigational sustained release treatments听for听wet AMD; our belief that DURAVYU has two potential blockbuster indications; our belief that DURAVYU鈥檚 potential real-world application in multiple retinal disease indications and de-risked trial designs position DURAVYU for clinical and commercial success; our expectations regarding timing for the completion of clinical trial enrollment and the timing of the availability and release of clinical data; our belief that rapid trial enrollment in LUGANO and LUCIA highlights physician and patient enthusiasm for DURAVYU, which we believe is driven by an established and familiar trial design, robust Phase 2 data, and a strong safety profile; our expectations regarding cash runway; our optimism that that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our belief that we are well positioned as the leader in ocular sustained drug delivery; our business strategies and objectives; and other statements regarding the Company鈥檚 future plans, objectives, strategies and beliefs, as identified by words such as 鈥渨ill,鈥� 鈥減otential,鈥� 鈥渃ould,鈥� 鈥渃an,鈥� 鈥渂elieve,鈥� 鈥渋ntends,鈥� 鈥渃ontinue,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥渕ay,鈥� or other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint鈥檚 actual results to be materially different than those expressed in or implied by EyePoint鈥檚 forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company鈥檚 clinical development activities, including DURAVYU; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company鈥檚 cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company鈥檚 product candidates; changes in the regulatory environment; disruptions at the FDA, including due to a reduction in the FDA鈥檚 workforce and/or inadequate funding for the FDA; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the Company鈥檚 ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney鈥檚 Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the Company鈥檚 Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at .听Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
/
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
| EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands) | |||||||
| 听 | 听 | 听 | 听 | ||||
| 听 | June听30, | 听 | December听31, | ||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Assets | 听 | 听 | 听 | ||||
| Current assets: | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 71,143 | 听 | 听 | $ | 99,704 | 听 |
| Marketable securities | 听 | 184,590 | 听 | 听 | 听 | 271,209 | 听 |
| Accounts and other receivables, net | 听 | 625 | 听 | 听 | 听 | 607 | 听 |
| Prepaid expenses and other current assets | 听 | 6,215 | 听 | 听 | 听 | 9,481 | 听 |
| Inventory | 听 | 2,678 | 听 | 听 | 听 | 2,305 | 听 |
| Total current assets | 听 | 265,251 | 听 | 听 | 听 | 383,306 | 听 |
| Operating lease right-of-use assets | 听 | 21,089 | 听 | 听 | 听 | 21,000 | 听 |
| Other assets | 听 | 14,807 | 听 | 听 | 听 | 14,159 | 听 |
| Total assets | $ | 301,147 | 听 | 听 | $ | 418,465 | 听 |
| Liabilities and stockholders' equity | 听 | 听 | 听 | ||||
| Current liabilities: | 听 | 听 | 听 | ||||
| Accounts payable and accrued expenses | $ | 31,163 | 听 | 听 | $ | 29,824 | 听 |
| Deferred revenue | 听 | 鈥� | 听 | 听 | 听 | 17,784 | 听 |
| Other current liabilities | 听 | 2,012 | 听 | 听 | 听 | 1,440 | 听 |
| Total current liabilities | 听 | 33,175 | 听 | 听 | 听 | 49,048 | 听 |
| Deferred revenue - noncurrent | 听 | 鈥� | 听 | 听 | 听 | 10,853 | 听 |
| Operating lease liabilities - noncurrent | 听 | 21,815 | 听 | 听 | 听 | 21,858 | 听 |
| Other noncurrent liabilities | 听 | 148 | 听 | 听 | 听 | 205 | 听 |
| Total liabilities | 听 | 55,138 | 听 | 听 | 听 | 81,964 | 听 |
| Stockholders' equity: | 听 | 听 | 听 | ||||
| Capital | 听 | 1,222,814 | 听 | 听 | 听 | 1,208,489 | 听 |
| Accumulated deficit | 听 | (977,637 | ) | 听 | 听 | (873,016 | ) |
| Accumulated other comprehensive income | 听 | 832 | 听 | 听 | 听 | 1,028 | 听 |
| Total stockholders' equity | 听 | 246,009 | 听 | 听 | 听 | 336,501 | 听 |
| Total liabilities and stockholders' equity | $ | 301,147 | 听 | 听 | $ | 418,465 | 听 |
| 听 | 听 | 听 | 听 | ||||
| EYEPOINT PHARMACEUTICALS, INC. AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (In thousands, except per share data) | |||||||||||||||
| 听 | 听 | 听 | 听 | ||||||||||||
| 听 | Three Months Ended | 听 | Six Months Ended | ||||||||||||
| 听 | June听30, | 听 | June听30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Revenues: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Product sales, net | $ | 鈥� | 听 | 听 | $ | 1,068 | 听 | 听 | $ | 715 | 听 | 听 | $ | 1,726 | 听 |
| License and collaboration agreements | 听 | 5,333 | 听 | 听 | 听 | 7,782 | 听 | 听 | 听 | 16,382 | 听 | 听 | 听 | 18,345 | 听 |
| Royalty income | 听 | 鈥� | 听 | 听 | 听 | 627 | 听 | 听 | 听 | 12,689 | 听 | 听 | 听 | 1,090 | 听 |
| Total revenues | 听 | 5,333 | 听 | 听 | 听 | 9,477 | 听 | 听 | 听 | 29,786 | 听 | 听 | 听 | 21,161 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cost of sales | 听 | 165 | 听 | 听 | 听 | 1,401 | 听 | 听 | 听 | 970 | 听 | 听 | 听 | 2,160 | 听 |
| Research and development | 听 | 55,498 | 听 | 听 | 听 | 29,822 | 听 | 听 | 听 | 114,072 | 听 | 听 | 听 | 60,011 | 听 |
| Sales and marketing | 听 | 35 | 听 | 听 | 听 | 50 | 听 | 听 | 听 | 70 | 听 | 听 | 听 | 56 | 听 |
| General and administrative | 听 | 11,862 | 听 | 听 | 听 | 12,750 | 听 | 听 | 听 | 25,738 | 听 | 听 | 听 | 26,801 | 听 |
| Total operating expenses | 听 | 67,560 | 听 | 听 | 听 | 44,023 | 听 | 听 | 听 | 140,850 | 听 | 听 | 听 | 89,028 | 听 |
| Loss from operations | 听 | (62,227 | ) | 听 | 听 | (34,546 | ) | 听 | 听 | (111,064 | ) | 听 | 听 | (67,867 | ) |
| Other income (expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest and other income, net | 听 | 2,894 | 听 | 听 | 听 | 3,720 | 听 | 听 | 听 | 6,536 | 听 | 听 | 听 | 7,757 | 听 |
| Total other income, net | 听 | 2,894 | 听 | 听 | 听 | 3,720 | 听 | 听 | 听 | 6,536 | 听 | 听 | 听 | 7,757 | 听 |
| Net loss before provision for income taxes | $ | (59,333 | ) | 听 | $ | (30,826 | ) | 听 | $ | (104,528 | ) | 听 | $ | (60,110 | ) |
| Provision for income taxes | 听 | (93 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (93 | ) | 听 | 听 | 鈥� | 听 |
| Net loss | $ | (59,426 | ) | 听 | $ | (30,826 | ) | 听 | $ | (104,621 | ) | 听 | $ | (60,110 | ) |
| Net loss per common share - basic and diluted | $ | (0.85 | ) | 听 | $ | (0.58 | ) | 听 | $ | (1.50 | ) | 听 | $ | (1.13 | ) |
| Weighted average common shares outstanding - basic and diluted | 听 | 69,926 | 听 | 听 | 听 | 53,206 | 听 | 听 | 听 | 69,847 | 听 | 听 | 听 | 53,059 | 听 |
FAQ
What were EyePoint's (EYPT) Q2 2025 financial results?
When will DURAVYU Phase 3 trial results for wet AMD be released?
How many patients were enrolled in EyePoint's Phase 3 DURAVYU trials?
How long will EyePoint's current cash position last?
What is the status of EyePoint's manufacturing facility for DURAVYU?
